Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.46 |
| ▸ | SELE | P16581 | 6/20 | 0.46 |
| ▸ | MAG | P20916 | 10/20 | 0.44 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959371 | 0.95 | SELP (0.46) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL13312725 | 0.94 | SELE (0.41) | SELPSELLSELEMAG | |
| SCHEMBL11962144 | 0.83 | MAG (0.53) | SELPSELLSELEMAG | |
| SCHEMBL12421186 | 0.81 | SELE (0.50) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL12420956 | 0.81 | SELE (0.41) | SELPSELE | |
| SCHEMBL15434912 | 0.80 | SELE (0.43) | SELPSELLSELEMAGSIGLEC7 | |
| SCHEMBL12257341 | 0.80 | SELE (0.48) | SELPSELLSELEMAG | |
| SCHEMBL14557942 | 0.80 | SELE (0.59) | SELPSELE | |
| SCHEMBL22247243 | 0.80 | SELE (0.59) | SELPSELE | |
| SCHEMBL11962136 | 0.77 | MAG (0.54) | SELPSELLSELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELP 2/4885SELL 4/4885SELE 1/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELP 2/4885SELL 4/4885SELE 1/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELP 2/4885SELL 4/4885SELE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.